# An Antibody-armored Dendritic Cell in Patients With Solid Tumors

> **NCT07479667** · PHASE1 · RECRUITING · sponsor: **Shanghai Cell Therapy Group Co.,Ltd** · enrollment: 8 (estimated)

## Conditions studied

- Solid Cancers
- Adjuvant Therapy

## Interventions

- **BIOLOGICAL:** Armored Dendritic Cell Injection

## Key facts

- **NCT ID:** NCT07479667
- **Lead sponsor:** Shanghai Cell Therapy Group Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-05
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479667, "An Antibody-armored Dendritic Cell in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07479667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*